# Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)

> **NCT01190072** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 120 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01190072
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01190072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01190072, "Lipid-lowering Therapy for Secondary Prevention in Patients Undergoing Elective Percutaneous Coronary Intervention (PCI)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01190072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*